Browsing by Author "People's Hospital of Guangxi Zhuang Autonomous Region"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • No Thumbnail Available
    PublicationMetadata only
    Real-world use of the second-generation cobalt-chromium sirolimus-eluting stents: 12-month results from the prospective multicentre FOCUS registry
    (2012-12-01) Feng Zhang; Junbo Ge; Juying Qian; Lei Ge; Jun Zhou; Yuejin Yang; Fang Chen; Xiaoling Zhu; Shuzheng Lv; Zhizhong Li; Haichang Wang; Yin Liu; Yawei Xu; Zhanquan Li; Huigen Jin; Weiyi Fang; Xuchen Zhou; Lijun Jing; Yundai Chen; Changyong Zhou; Zhexun Lian; Yi An; Yongjian Yang; Zhixiong Zhong; Zuyi Yuan; Xiaofei Sun; Guotai Sheng; Zhenming Yan; Ren Ke Yi; Jian An; Bin Liu; Zesheng Xu; Xiaoqun Pu; Yongwen Qin; Shuangying Feng; Guosheng Fu; Chunlin Lai; Bo Yu; Tiemin Jiang; Lefeng Wang; Weiming Wang; Jianjun Peng; Hui Li; Wenyue Pang; Biao Xu; Haiming Shi; Meng Wei; Changqian Wang; Ying Zhu; Ningfu Wang; Shaoliang Chen; Qiang Fu; Shian Huang; Keng Wu; Yutian Tong; Zheng Zhang; Ge Zhang; Hesong Zeng; Hong Jiang; Wenwei Liu; Guoying Zhu; Ping Li; Xuekun Zhang; Zhimin Du; Yingfeng Liu; Weimin Li; Ling Liu; Ben He; Wei Gao; Dalin Jia; Jinchuan Yan; Shaorong Liu; Chuanhuan Zhang; Yimin Fang; Zhigang Tao; Jifu Li; He Huang; Xingui Guo; Xinghua Zhang; Tongbao Liu; Lianqun Cui; Jianming Xiao; Lianglong Chen; Jinfa Jiang; Chenzhi Lu; Xueqi Li; Peng Qu; Yan Wang; Honghua Ye; Jingtian Li; Yuqing Hou; Qiutang Zeng; Yuanze Jin; Dongju Jiang; Kanghua Ma; Dadong Zhang; Suwatchai Pornratanarangsi; Muhamad Munawar; Teguh Santoso; Fudan University; Fuwai Cardiovascular Hospital; Beijing Anzhen Hospital; Xijing Hospital; Tianjin Chest Hospital; Shanghai Tenth People's Hospital; People's Hospital of Liaoning Province; Putuo District Central Hospital of Shanghai; Shanghai Chest Hospital; Dalian Medical University; Guangdong General Hospital; Peoples' Liberation Army General Hospital; Qingdao University, School of Medicine; Chengdu Militar General Hospital; Meizhou People's Hospital; Xi'an Jiaotong University, School of Medicine; First People's Hospital of Jining City; Jiangxi Provincial People's Hospital; General Hospital of Fushun Mining Group; Shanxi Provincial Institute of Cardiovascular Disease; Jilin University; Cangzhou Central Hospital; Xiangya Hospital of Zhongnan University; Changhai Hospital; Xingtai Cardiovascular Disease Hospital; Zhejiang University; Shaanxi Provincial People's Hospital; Harbin Medical University; Armed Police Medical College Hospital; Beijing Red Cross Chaoyang Hospital; Peking University; Beijing Shijitan General Hospital; Daqing Oilfield General Hospital; Shengjing Hospital of China Medical University; The Affiliated DrumTower Hospital of Nanjing University Medical School; Shanghai Sixth People's Hospital; Xinhua Hospital; Hangzhou First People's Hospital; Nanjing First Hospital; Xuzhou Centre Hospital; Guangdong Medical College; Weifang Yidu Zhongxin Hospital; Lanzhou University; Kunming Medical College; Huazhong University of Science and Technology; Hubei General Hospital; Xiangfan City Central Hospital; Wuhan Asia Heart Hospital; First People's Hospital of Yulin City; Beijing Luhe Hospital; Sun Yat-Sen University; Zhujiang Hospital; People's Hospital of Guangxi Zhuang Autonomous Region; Renji Hospital; China Medical University Shenyang; Jiangsu University; Yantai Yuhuangding Hospital; Qilu Hospital of Shandong University; Xiangtan Central Hospital; Huadong Hospital; Shandong Provincial Hospital; Fujian Medical University; Tongji University; Tianjin First Central Hospital; Xiamen University; First People's Hospital of Ningbo City; Weifang Medical College; Southern Medical University; Wuhan Union Hospital; The 210th Hospital of PLA; Chongqing Medical University; Shanghai Minhang District Central Hospital; Mahidol University; Bina Waluya Cardiac Hospital; Medistra Hospital
    Aims: The FOCUS registry is a prospective, multicentre, web-based programme designed to collect clinical outcome data from real-world patients receiving the second-generation cobalt-chromium sirolimus-eluting stent (CoCr-SES). Methods and results: From March 2009 to February 2010, a total of 5,084 patients from 83 centres who were eligible to receive CoCr-SES were enrolled in the FOCUS registry. The primary endpoint was 12-month major adverse cardiac events (MACE, defined as the composite of cardiac death, myocardial infarction [MI] , and target vessel revascularisation [TVR]). One-year data were available for 5,013 (98.6%) of the 5,084 patients enrolled. The primary endpoint occurred in 174 (3.47%) of 5,013 patients, consisting of 43 (0.86%) cardiac deaths, 132 (2.63%) MI, and 46 (0.92%) TVR. According to the Academic Research Consortium definition, definite and probable stent thrombosis (ST) occurred in 0.52% (26/5,013) of patients, including 19 cases of early ST and 7 of late ST. The 12-month MACE rates were 3.73% and 2.60% for extended-use and standard-use patients, respectively (p=0.065). Conclusions: The second-generation CoCr-SES was associated with low rates of 12-month MACE and ST in a broad spectrum of patients, thereby confirming the clinical safety and efficacy of this stent in a real-world setting. © Europa Digital & Publishing 2012. All rights reserved.